Fig 2: Frequencies of PYGO2 and ZMYND8 copy number increase A., and CHD3 and KMT2A deletion B. across five subtypes of TCGA breast cancer samples. C. Expression levels of PYGO2, ZMYND8, CHD3, and KMT2A across five subtypes of TCGA breast cancer samples. The differences in PYGO2, ZMYND8, CHD3, and KMT2A mRNA levels among breast cancer subtypes are statistically significant (p < 0.05).

Fig 3: A. Expression levels of ZMYND8 across different AJCC stages of TCGA breast cancer samples. B. Kaplan-Meier plots of overall survival associated with mRNA expression levels of ZMYND8 in TCGA breast cancers. C. Multivariate analysis revealed that ZMYND8 expression was independent of prognostic variables influencing overall survival of TCGA breast cancer patients.

Fig 4: A. Representative images of cells stained with crystal violet show the effect of JQ-1 on growth and survival of ER-positive T47D and ER-negative SUM159 cells. B. Bar graphs show relative cells growth after JQ-1 treatment in T47D and SUM159 cells. C. Immunoblot and D. qRT-PCR analysis of ZMYND8 expression after treatment with JQ-1 in T47D and SUM159 cells (*p<0.05 and **p<0.01, Student's t-test). Protein levels of MYC were also measured by western blot after JQ-1 treatment in T47D and SUM159 cells.